Clearance Summary
LIAISON CMV IgM Serum Control Set received FDA 510(k) clearance under submission number K161526, sponsored by DiaSorin, Inc.. The device was reviewed via the Special premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 2016-06-30.
- Submission: K161526
- Applicant / Sponsor: DiaSorin, Inc.
- Clearance pathway: Special
- Review panel: Clinical Chemistry
- Device class: Class I
- Regulation citation: 21 CFR 862.1660
- Decision date: 2016-06-30
Classification & Regulation
This clearance is catalogued under FDA product code JJX and 21 CFR 862.1660, within the Clinical Chemistry review panel as a Class I device.